ArticleNeurosurgical review2026
Predicting early recurrence of craniopharyngioma using multi-omics radiomic modeling: a retrospective cohort study.
Article in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniopharyngiomas (CPs) are benign tumors arising in the sellar and suprasellar regions, but they frequently recur after surgery because of their proximity to critical neurovascular and hypothalamic structures. This study aimed to develop and validate a habitat-based multimodal radiomics model for early postoperative recurrence prediction in CP. This retrospective single-center cohort included 106 patients with pathologically confirmed CP selected from 136 consecutive surgically treated cases. Preoperative magnetic resonance imaging (MRI) scans (T1-weighted imaging, contrast-enhanced T1-weighted imaging, and T2 -weighted imaging) were used for tumor habitat analysis based on unsupervised clustering of voxel-level radiomic features. Radiomic features were extracted from whole-tumor and habitat-defined subregions, followed by feature selection within the training cohort using univariate filtering, correlation pruning, minimum redundancy maximum relevance (mRMR), and least absolute shrinkage and selection operator (LASSO). Clinical, radiomics, habitat-based, and Combined models. Model performance was evaluated using Receiver Operating Characteristic (ROC), calibration, and decision curve analyses. Shapley Additive exPlanations (SHAP) analysis and representative habitat maps were used for model interpretability. Among the evaluated classifiers, the ExtraTrees model showed the most stable discrimination performance across the training and validation cohorts. The HabitatAll model achieved an AUC of 0.891 in both cohorts, while the Combined model showed the best overall predictive performance, with AUCs of 0.944 and 0.891 in the training and validation cohorts, respectively, and the lowest Brier scores. SHAP analysis identified T1C-derived and H3-related habitat features as major contributors to recurrence prediction. Representative habitat maps showed that H3 was frequently distributed in the peripheral portion of the tumor in both recurrent and non-recurrent cases. This study developed a promising habitat-based multimodal radiomics model for early postoperative recurrence prediction in craniopharyngioma. The Combined model demonstrated the most favorable overall discrimination and calibration. H3-related habitat features may capture intratumoral heterogeneity associated with recurrence risk. However, given the retrospective single-center design, these findings should be interpreted as preliminary and require further validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.